Cangene Corporation, headquartered in Winnipeg, Manitoba, has been a successful biopharmaceutical company for almost three decades. Revenues for the 2009 year were $238.8 million, compared with $166.1 million last year, an increase of 44%. Net income for the year was $59.9 million or $0.86 per share, compared with $29.6 million or $0.42 per share a year earlier.

Cangene is focused largely on developing and manufacturing hyperimmune products used for treating infectious diseases and other biodefense applications that seem to increasingly continue to threaten our health and economy. Cangene currently has four FDA-approved products -- three hyperimmunes, WinRho, VIG, and HepaGam B, and one recombinant protein, Accretropin (hGH).

Cangene’s fully integrated operations allow the company to take drugs from development all the way through to commercial manufacturing. It operates three large manufacturing facilities - two in Winnipeg, Manitoba and one in Baltimore, Maryland - where it produces its own products and undertakes contract manufacturing for a number of companies. Cangene operates three U.S. and one Canadian plasma-collection facilities. 

Cangene is focused on developing therapeutics for infectious diseases, and the Company uses patented manufacturing processes to produce plasma-derived and recombinant therapeutic proteins. In addition, the Company has several more products in development at various stages. Three of Cangene's products have been accepted into the U.S. Strategic National Stockpile – botulism antitoxin, anthrax immune globulin and vaccinia immune globulin, a product used to counteract certain complications that may arise from smallpox vaccination.

Capitalizing on its drug manufacturing expertise, Cangene also operates a significant contract research and manufacturing business using its Winnipeg facilities and the resources of Baltimore, Maryland-based Chesapeake Biological Laboratories, Inc. (a wholly owned subsidiary).